ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-4.37%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$520M
AUM Growth
+$520M
(+7.1%)
Cap. Flow
+$56.8M
Cap. Flow
% of AUM
10.93%
Top 10 Holdings %
Top 10 Hldgs %
45.71%
Holding
253
New
46
Increased
68
Reduced
40
Closed
49
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$14.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$9.17M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
$8.55M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
| 5 |
RAPT Therapeutics
RAPT
|
$5.85M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$11.7M |
| 2 |
Ascendis Pharma
ASND
|
$10.9M |
| 3 |
Mineralys Therapeutics
MLYS
|
$9.18M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$6.59M |
| 5 |
Sanofi
SNY
|
$4.8M |
Sector Composition
| 1 | Healthcare | 80.96% |
| 2 | Financials | 3.59% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Utilities | 0.02% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ASPC
51
A SPAC III Acquisition Corp. Class A Ordinary Shares
ASPC
$83M
| $2.16M | 0.4% |
+215,000
| New | +$2.16M |
|
52
Rhythm Pharmaceuticals
RYTM
$6.93B
| $1.95M | 0.36% |
36,890
+5,949
| +19% | +$315K |
|
53
Delcath Systems
DCTH
$386M
| $1.9M | 0.35% |
149,385
| – | – |
|
54
Crinetics Pharmaceuticals
CRNX
$3.22B
| $1.78M | 0.33% |
53,125
| – | – |
|
55
KALA BIO
KALA
$92.3M
| $1.71M | 0.32% |
298,955
+78,582
| +36% | +$450K |
|
56
Vir Biotechnology
VIR
$739M
| $1.62M | 0.3% |
250,000
+185,933
| +290% | +$1.2M |
|
57
Rocket Pharmaceuticals
RCKT
$347M
| $1.61M | 0.3% |
241,800
+30,400
| +14% | +$203K |
|
58
Taysha Gene Therapies
TSHA
$777M
| $1.48M | 0.28% |
1,066,309
+888,602
| +500% | +$1.24M |
|
59
Viking Therapeutics
VKTX
$3.09B
| $1.43M | 0.27% |
59,413
+50,113
| +539% | +$1.21M |
|
60
Fulcrum Therapeutics
FULC
$351M
| $1.41M | 0.26% |
490,532
+294,284
| +150% | +$848K |
|
|
CRGX
61
DELISTED
CARGO Therapeutics
CRGX
| $1.39M | 0.26% |
+341,515
| New | +$1.39M |
|
|
ORKA
62
Oruka Therapeutics, Inc. Common Stock
ORKA
$585M
| $1.36M | 0.25% |
+132,780
| New | +$1.36M |
|
63
Soleno Therapeutics
SLNO
$3.56B
| $1.35M | 0.25% |
18,830
-18,000
| -49% | -$1.29M |
|
|
VRNA
64
Verona Pharma
VRNA
$9.17B
| $1.27M | 0.24% |
20,000
-9,100
| -31% | -$578K |
|
|
CKPT
65
DELISTED
Checkpoint Therapeutics
CKPT
| $1.24M | 0.23% |
+305,800
| New | +$1.24M |
|
66
Aldeyra Therapeutics
ALDX
$353M
| $1.22M | 0.23% |
211,579
-436,381
| -67% | -$2.51M |
|
67
Korro Bio
KRRO
$223M
| $1.2M | 0.22% |
68,715
+10,737
| +19% | +$187K |
|
|
CTNM
68
Contineum Therapeutics
CTNM
$306M
| $1.18M | 0.22% |
168,765
+86,531
| +105% | +$604K |
|
|
TECX
69
Tectonic Therapeutic, Inc. Common Stock
TECX
$319M
| $1.11M | 0.21% |
62,603
+3,895
| +7% | +$69K |
|
70
Viridian Therapeutics
VRDN
$1.58B
| $1.06M | 0.2% |
79,000
+53,000
| +204% | +$714K |
|
71
VistaGen Therapeutics
VTGN
$110M
| $1.05M | 0.2% |
420,765
+299,304
| +246% | +$748K |
|
72
Pfizer
PFE
$141B
| $1.04M | 0.19% |
41,050
+6,000
| +17% | +$152K |
|
|
AACT
73
Ares Acquisition Corporation II
AACT
$706M
| $1.01M | 0.19% |
90,466
-48,500
| -35% | -$541K |
|
74
Surgery Partners
SGRY
$2.88B
| $950K | 0.18% |
+40,000
| New | +$950K |
|
75
Kiniksa Pharmaceuticals
KNSA
$2.59B
| $920K | 0.17% |
41,412
-124,994
| -75% | -$2.78M |
|